Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros




Base de datos
Intervalo de año de publicación
1.
Hinyokika Kiyo ; 54(8): 537-42, 2008 Aug.
Artículo en Japonés | MEDLINE | ID: mdl-18788443

RESUMEN

Folic acid plays an important role in proliferating cells and tissues of the fetus. A randomized control trial demonstrated in 1991 that 4 mg of folic acid supplements successfully prevented 72% of recurrence of neural tube defects (NTDs) in women who had had afflicted pregnancy. In 2000, the Japanese Government recommended women of childbearing age to take 400 microgram of folate supplements per day from 4 weeks prior to and 12 weeks after conception. A questionnaire study was performed in pregnant women by post on their awareness of the role folic acid plays, their life style, and folate intake by dietary consumption. Thirty-five percent of 1,251 pregnant women were aware of the important role of folic acid in the critical stage of fetal development and 31% actually took the supplement. Information on folic acid was obtained through mass media in 47% of the women, through the internet in 17%, through healthcare providers in 13% and so forth. The food record analysis revealed that the dietary intake of folic acid averaged 341 microg/day that was 60 microg less than what was recommended by the Government and that 33 of 86 women took the supplement. Overall, a half of pregnant women are required to take 400 microg folate supplement per day. It is to be stressed that primary prevention of NTDs by periconceptional intake of folic acid is a major public health opportunity and that prevention is more important than cure in the management of NTDs.


Asunto(s)
Concienciación , Ácido Fólico/administración & dosificación , Defectos del Tubo Neural/prevención & control , Adolescente , Adulto , Femenino , Humanos , Atención Preconceptiva , Embarazo , Atención Prenatal , Riesgo
2.
J Obstet Gynaecol Res ; 33(5): 606-11, 2007 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17845316

RESUMEN

AIM: Placenta accreta is an abnormally firm attachment of placental villi to the uterine wall, which may cause postpartum hemorrhage resulting in maternal morbidity and mortality. The purpose of the present study was to clarify the incidence, clinical background and prognosis of placenta previa increta/percreta treated with different modalities in Japan. METHODS: Medical records of cases with placenta previa increta/percreta in eight tertiary centers between January 1994 and December 2004 were reviewed. Placenta accreta without actual invasion into the myometrium confirmed by pathology was not included in placenta increta/percreta. Details of obstetric history, maternal background, ultrasonographical findings, the course of delivery, subsequent complications and management were noted. RESULTS: Among the total of 59,008 deliveries, 45,261 were by the vaginal route (76.7%) and 13 747 by cesarean section (23.3%). In this study, 408 cases were diagnosed as placenta previa (0.69%), 18 of these being placenta increta and 5 placenta percreta. Only 1.1% of cases of placenta previa without prior cesarean section were increta/percreta, in contrast to 37% of placenta previa after prior cesarean sections. Mean intraoperation blood loss was 3630 +/- 2216 g (increta) and 12,140 +/- 8343 g (percreta). One patient with placenta previa percreta died of hemorrhage. Stepwise treatment (cesarean section without separation of the placenta, arterial embolization and hysterectomy) was applied for 4 cases, which had the least blood loss. CONCLUSIONS: Placenta previa increta/percreta is a life-threatening disease. Patients who undergo hysterectomy after uterine arterial embolization demonstrate reduced intraoperation blood loss, and this treatment should be incorporated to reduce maternal morbidity.


Asunto(s)
Placenta Previa/diagnóstico por imagen , Placenta Previa/terapia , Cesárea , Embolización Terapéutica , Femenino , Humanos , Incidencia , Japón/epidemiología , Placenta Previa/epidemiología , Placenta Previa/patología , Hemorragia Posparto/patología , Hemorragia Posparto/prevención & control , Embarazo , Estudios Retrospectivos , Ultrasonografía Prenatal
3.
Early Hum Dev ; 67(1-2): 19-28, 2002 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-11893432

RESUMEN

Four-hydroxynonenal (HNE) has been proposed as an important marker of radical-induced lipid peroxidation. The principal objective of this study was to assess the occurrence of lipid peroxidation in normal perinatal brain and brains with one form of pontosubicular neuronal necrosis (PSN). Immunochemical studies using an antibody against HNE-modified protein were performed in controls aged from 20 weeks of gestation to 64 years, and patients with PSN. Immunohistochemical study showed developmental and aging changes of positive staining in Purkinje cells and pontine neurons (27 weeks-7 months, 50 and 64 years). In addition, karyorrhectic cells in pontine nuclei with PSN were positively stained. Immunoblotting revealed that a 75-kDa protein, which is speculated to be mitochondrial complex-1 protein, was the most intensely expressed among multiple immunoreactive proteins. Our results identified the presence of oxidative stress in the perinatal neuron, and this oxidative stress may contribute to some forms of karyorrhectic death.


Asunto(s)
Aldehídos/metabolismo , Hipocampo/metabolismo , Enfermedades del Prematuro/metabolismo , Recien Nacido Prematuro/metabolismo , Puente/metabolismo , Células de Purkinje/metabolismo , Adolescente , Niño , Preescolar , Edad Gestacional , Hipocampo/embriología , Hipocampo/patología , Humanos , Lactante , Recién Nacido , Enfermedades del Prematuro/patología , Persona de Mediana Edad , Necrosis , Puente/embriología , Puente/patología , Células de Purkinje/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA